Baseline patient demographics in the induction phase of the ALMS trial
| Characteristic | Total (N= 370) |
| Gender (n (%)) | |
| Male | 57 (15.41) |
| Female | 313 (84.59) |
| Race (n (%)) | |
| Caucasian | 147 (39.73) |
| Asian | 123 (33.24) |
| Black | 46 (12.43) |
| Other races | 54 (14.59) |
| Region (n (%)) | |
| Asia | 117 (31.62) |
| Latin America (LA) | 106 (28.65) |
| Europe | 61 (16.49) |
| USA/Canada | 75 (20.27) |
| Rest of the world | 11 (2.97) |
| Race/location (n (%)) | |
| Asian | 123 (33.24) |
| Black in other regions | 15 (4.05) |
| Black in the USA | 31 (8.38) |
| Caucasian in Europe | 51 (13.78) |
| Caucasian in Latin America and other regions | 66 (17.84) |
| Caucasian in USA/Canada | 30 (8.11) |
| Other races | 54 (14.59) |
| Age at baseline (years; mean±SD) | 31.8±10.6 |
| Disease duration of lupus nephritis (years; median (range)) | 1.0 (1 to 23) |
| Disease duration of lupus nephritis, by category (n (%)) | |
| ≤1 year | 236 (63.78) |
| 2–4 years | 69 (18.65) |
| >4 years | 65 (17.57) |
| Height (m; mean±SD) | 1.62±0.09 |
| Weight (kg; mean±SD) | 64.21±15.12 |
| Diabetes (n (%)) | 6 (1.62) |
| Hypertension (n (%)) | 202 (54.59) |
| Steroid dose (prednisone mg/day) (n (%)) | |
| <50 | 91 (24.59) |
| 50–60 | 94 (25.41) |
| >60 | 175 (47.30) |
| NA | 10 (2.70) |
ALMS, Aspreva Lupus Management Study.